These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 28474165

  • 1. Evaluation of 99mTc-3PRGD2 integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with 18F-FDG metabolic imaging.
    Zheng J, Miao W, Huang C, Lin H.
    Ann Nucl Med; 2017 Jul; 31(6):486-494. PubMed ID: 28474165
    [Abstract] [Full Text] [Related]

  • 2. [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT.
    Zheng S, Chen Z, Huang C, Chen Y, Miao W.
    Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
    [Abstract] [Full Text] [Related]

  • 3. Comparison of [99mTc]3PRGD2 Imaging and [18F]FDG PET/CT in Breast Cancer and Expression of Integrin αvβ3 in Breast Cancer Vascular Endothelial Cells.
    Chen Z, Fu F, Li F, Zhu Z, Yang Y, Chen X, Jia B, Zheng S, Huang C, Miao W.
    Mol Imaging Biol; 2018 Oct; 20(5):846-856. PubMed ID: 29497956
    [Abstract] [Full Text] [Related]

  • 4. Noninvasive detection of human-induced pluripotent stem cell (hiPSC)-derived teratoma with an integrin-targeting agent (99m)Tc-3PRGD2.
    Li Y, Liu Z, Dong C, He P, Liu X, Zhu Z, Jia B, Li F, Wang F.
    Mol Imaging Biol; 2013 Feb; 15(1):58-67. PubMed ID: 22707047
    [Abstract] [Full Text] [Related]

  • 5. Integrin Imaging with 99mTc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer.
    Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, Li S, Luo J, Luo Y, Cui Q, Zheng K, Liu Z, Shi J, Li F, Wang F, Zhu Z.
    Radiology; 2016 Dec; 281(3):958-966. PubMed ID: 27479638
    [Abstract] [Full Text] [Related]

  • 6. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study.
    Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Liu S, Shi J, Liu Z, Zhao Z, Wang F, Li F.
    J Nucl Med; 2012 May; 53(5):716-22. PubMed ID: 22499615
    [Abstract] [Full Text] [Related]

  • 7. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, Ferro-Flores G, García-Becerra R, Estrada G, Gómez-Argumosa E, Izquierdo-Sánchez V.
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [Abstract] [Full Text] [Related]

  • 8. Imaging of Integrin αvβ3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99mTc-IDA-D-[c(RGDfK)]2.
    Song YS, Park HS, Lee BC, Jung JH, Lee HY, Kim SE.
    Cancer Biother Radiopharm; 2017 Oct; 32(8):288-296. PubMed ID: 29053416
    [Abstract] [Full Text] [Related]

  • 9. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
    Liu Z, Jia B, Shi J, Jin X, Zhao H, Li F, Liu S, Wang F.
    Bioconjug Chem; 2010 Mar 17; 21(3):548-55. PubMed ID: 20184307
    [Abstract] [Full Text] [Related]

  • 10. Assessing activation of hepatic stellate cells by (99m)Tc-3PRGD2 scintigraphy targeting integrin αvβ3: a feasibility study.
    Zhang X, Xin J, Shi Y, Xu W, Yu S, Yang Z, Liu C, Cao L, Guo Q.
    Nucl Med Biol; 2015 Mar 17; 42(3):250-5. PubMed ID: 25530210
    [Abstract] [Full Text] [Related]

  • 11. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2.
    Zhao D, Jin X, Li F, Liang J, Lin Y.
    J Nucl Med; 2012 Dec 17; 53(12):1872-7. PubMed ID: 23071350
    [Abstract] [Full Text] [Related]

  • 12. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.
    Sancey L, Ardisson V, Riou LM, Ahmadi M, Marti-Batlle D, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP.
    Eur J Nucl Med Mol Imaging; 2007 Dec 17; 34(12):2037-47. PubMed ID: 17674000
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of 99m Tc-3PRGD2 SPECT imaging on angiogenesis in animal models of lung cancer.
    Wu Y, Wang Y, Yang Z, Teng C, Guo Z.
    Thorac Cancer; 2022 Nov 17; 13(21):3025-3031. PubMed ID: 36104010
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.
    Chen G, Ouyang Z, Wang F, Wu H, Jia B, Chordia MD.
    Cancer Invest; 2017 Feb 07; 35(2):108-115. PubMed ID: 28135863
    [Abstract] [Full Text] [Related]

  • 15. Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin αvβ3-targeting Radiotracer.
    Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, Shi J, Zhao H, Jia B, Liu Z, Wang F.
    Radiology; 2016 May 07; 279(2):502-12. PubMed ID: 26669696
    [Abstract] [Full Text] [Related]

  • 16. Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3.
    Shao G, Zhou Y, Wang F, Liu S.
    Mol Imaging; 2013 May 07; 12(1):39-48. PubMed ID: 23348790
    [Abstract] [Full Text] [Related]

  • 17. Clinical Value of 99mTc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Level.
    Gao R, Zhang GJ, Wang YB, Liu Y, Wang F, Jia X, Liang YQ, Yang AM.
    Sci Rep; 2018 Jan 11; 8(1):473. PubMed ID: 29323252
    [Abstract] [Full Text] [Related]

  • 18. Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging.
    Zhao ZQ, Yang Y, Fang W, Liu S.
    Nucl Med Biol; 2016 Nov 11; 43(11):661-669. PubMed ID: 27556955
    [Abstract] [Full Text] [Related]

  • 19. Imaging of bronchioloalveolar carcinoma in the mice with the αⅤβ3 integrin-targeted tracer (99m)Tc-RGD-4CK.
    Liu B, Feng Y, Zhang JY, Li HM, Li XD, Jia HL, Li ZY, Feng J.
    Transl Res; 2013 Sep 11; 162(3):174-80. PubMed ID: 23867618
    [Abstract] [Full Text] [Related]

  • 20. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation.
    Takei T, Kuge Y, Zhao S, Sato M, Strauss HW, Blankenberg FG, Tait JF, Tamaki N.
    J Nucl Med; 2005 May 11; 46(5):794-9. PubMed ID: 15872353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.